Healthcare Industry News: linear accelerator
News Release - November 30, 2015
Proton Partners International to Fight Cancer with Elekta Radiotherapy EquipmentSTOCKHOLM--(Healthcare Sales & Marketing Network)--Elekta (EKTA-B.ST) is to help Proton Partners International achieve its goal of creating hubs of excellence for advanced cancer treatment in the UK by providing the latest technology in radiotherapy.
Proton Partners International is to open centers in the UK. In addition to proton therapy, the centers will offer radiotherapy and chemotherapy to treat, private patients under medical insurance and self-pay patients and NHS patients.
Proton Partners will acquire Elekta Versa HD™ (http://www.versahd.com/) systems, the most modern linear accelerator on the market, as well as Elekta MOSAIQ® offering a fully integrated OIS consisting of MOSAIQ® radiation oncology (https://www.elekta.com/software-solutions/care-management/mosaiq-radiation-oncology.html), MOSAIQ® medical oncology (https://www.elekta.com/software-solutions/care-management/mosaiq-medical-oncology/) and MOSAIQ proton therapy. The Versa HD systems and MOSAIQ software will be installed at the centers in Newport, Wales and Northumberland, England. The order is valued at more than GBP 5 million and was booked during Elekta's second fiscal quarter.
Mike Moran, Chief Executive Officer of Proton Partners International, says: “We are committed to providing the highest quality of treatment at our centers and as such we are working with class-leading partners. We are pleased to be working in partnership with Elekta, which is renowned for the excellence of its products and services.”
Ian Alexander, Chief Commercial Officer at Elekta, says: “We are very pleased to support Proton Partners in transforming care in the UK. Elekta’s comprehensive, efficient cancer care management solutions can help Proton Partners to achieve their goal of treating more than 2,000 patients annually.”
According to Cancer Research UK, the number of new cancer cases each year in the UK is expected to reach around 432,000 by 2030, and half of these patients should receive radiotherapy at some point in their treatment. The precision and speed of Versa HD, it’s advanced beam-shaping, imaging and high dose rate technologies make it perfect for treating both conventional and complex cancer cases.
Paddy Greally, Elekta’s Business Unit Manager in the UK & Ireland, adds: “Proton Partners and Elekta are working together to bring the best and most innovative radiotherapy to cancer patients in the UK.”
The above information is such that Elekta AB (publ) shall make public in accordance with the Securities Market Act and/or the Financial Instruments Trading Act. The information was published at 07:30 CET on November 30, 2015. About Elekta Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both health care providers and patients, Elekta aims to improve, prolong and even save patient lives. Today, Elekta solutions in oncology and neurosurgery are used in over 6,000 hospitals worldwide. Elekta employs around 3,800 employees globally. The corporate headquarters is located in Stockholm, Sweden, and the company is listed on NASDAQ Stockholm. Website: www.elekta.com.
About Proton Partners International Limited
Proton Partners International is a private limited company, registered in Wales. The company was formed following discussions between Professor Karol Sikora, former head of the World Health Organisation’s cancer programme, Professor Sir Chris Evans, the leading life sciences entrepreneur, and Neil Woodford, founding partner of Woodford Investment Management. Institutional and private investors have committed to almost £100m equity finance in the company.
Professor Gordon McVie, Senior Consultant at the European Institute of Oncology, which partners the Italian Hadron Centre in Pavia, has been appointed chairman and Professor Karol Sikora is chief medical adviser to the company.
For more information on Proton Partners, please visit: http://proton-int.com/
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.